Sartorius Stedim Biotech S.A. is a leading international provider of innovative equipment and services for the biopharmaceutical industry and life sciences research. The company specializes in single-... Sartorius Stedim Biotech S.A. is a leading international provider of innovative equipment and services for the biopharmaceutical industry and life sciences research. The company specializes in single-use technologies, laboratory instruments, consumables, and bioprocess solutions that support the development, quality assurance, and production of biotech medications, vaccines, and therapies, including cell and gene treatments. Key offerings include bioreactor systems like Ambr® and Biostat®, chromatography tools such as BioSMB and CIM® columns, and advanced analytics for process optimization, enabling faster, safer, and more economical manufacturing. Headquartered in Aubagne, France, with production sites in Germany, France, Puerto Rico, and a global network across more than 30 countries, it employs over 10,000 people and generates recurring revenue primarily from sterile single-use products. As part of the Sartorius Group, it holds strong market positions, driven by demographic trends, medical progress, and expansion in North America and Asia, while focusing on sustainability and innovation through acquisitions and partnerships.
Sartorius Stedim Biotech's EU Taxonomy Data Preview
In 2025, Sartorius Stedim Biotech was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Sartorius Stedim Biotech has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Sartorius Stedim Biotech are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
1.2 CE - Manufacture of electrical and electronic equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Metric
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
7.7 CCM/CCA - Acquisition and ownership of buildings
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Metric
2025
2024
2023
2022 - 2017
Total Taxonomy Aligned Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Total Taxonomy Eligible Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
7.7 CCM/CCA - Acquisition and ownership of buildings
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
0000000
Limited Data Preview
You are viewing a limited preview of Sartorius Stedim Biotech’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories, at both aggregate and activity level, with historical coverage back to undefined.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Verified Sources Behind Sartorius Stedim Biotech’s EU Taxonomy Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sartorius Stedim Biotech’s data sources below and access millions more through our Disclosure Search.
a. Sartorius Stedim Biotech's Universal Registration Document (URD) 2025
b. Sartorius Stedim Biotech's Universal Registration Document (URD) 2024
Insights into Sartorius Stedim Biotech's Revenues from Sustainable Activities
In 2025, Sartorius Stedim Biotech reported EU Taxonomy-eligible revenues of EUR 631.40 million, representing 21% of its total turnover. Of this amount, EUR 23.20 million of Sartorius Stedim Biotech's revenues was classified as EU Taxonomy-aligned, indicating that 1% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Sartorius Stedim Biotech's Taxonomy-Eligible Turnover Over Time
Total Taxonomy Eligible Turnover
Total Taxonomy Aligned Turnover
Have Sartorius Stedim Biotech's revenues become more sustainable over time?
Compared to the previous year (2024), Sartorius Stedim Biotech's taxonomy-aligned revenues remained relatively stable, indicating that Sartorius Stedim Biotech maintained operational continuity , with no significant changes in the scale of sustainable activities or the coverage of its taxonomy-aligned reporting.a, b
How much of Sartorius Stedim Biotech's revenue is eligible under the EU Taxonomy?
In 2025, Sartorius Stedim Biotech reported that EUR 631.40 million of its revenue was eligible under the EU Taxonomy, representing 21% of the company's total turnover. Of this amount, EUR 23.20 million (1% of total revenue) was classified as Taxonomy-aligned. This means that 20% of Sartorius Stedim Biotech's revenue is eligible but not aligned, indicating that these activities did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards.a
How much of Sartorius Stedim Biotech's eligible revenue is aligned with the EU Taxonomy?
In 2025, Sartorius Stedim Biotech reported that EUR 23.20 million of its revenue was aligned under the EU Taxonomy, representing 1% of its total turnover.a
This low alignment highlights either a limited focus on green activities or early-stage adoption of sustainability frameworks, underscoring opportunities for further alignment with EU climate objectives.
Sartorius Stedim Biotech's Contribution to Environmental Objectives
Total Taxonomy Aligned Turnover
How is Sartorius Stedim Biotech's taxonomy-aligned revenue distributed across the EU environmental objectives?
In 2025, Sartorius Stedim Biotech reported that its taxonomy-aligned revenue was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 0%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 1%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much revenue does Sartorius Stedim Biotech earn from selling climate-related solutions ?
In 2025, Sartorius Stedim Biotech reported that EUR 0 of its total revenue was associated with activities contributing to the EU taxonomy climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This accounted for 0% of the company's total revenue,indicating that Sartorius Stedim Biotechhas limited exposureon solutions that support climate action through its commercial activities.a
Insights into Sartorius Stedim Biotech's CAPEX from Sustainable Activities
In 2025, Sartorius Stedim Biotech reported EU Taxonomy-eligible CAPEX of EUR 361.80 million,representing 79% of its total CAPEX. Of this amount, EUR 0 of Sartorius Stedim Biotech's CAPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Sartorius Stedim Biotech's Taxonomy-Eligible Capex Over Time
Total Taxonomy Eligible Capex
Total Taxonomy Aligned Capex
Have Sartorius Stedim Biotech's increased its investment in sustainable activities over time?
Compared to the previous year (2024), Sartorius Stedim Biotech's taxonomy-aligned CAPEX decreased by 100%,suggesting that Sartorius Stedim Biotech may have scaled back investments in sustainable projects, reprioritized its capital deployment, or reduced transparency in its taxonomy-aligned disclosures.a, b
Insights into Sartorius Stedim Biotech's OPEX from Sustainable Activities
In 2025, Sartorius Stedim Biotech reported EU Taxonomy-eligible OPEX of EUR 28.70 million,representing 24% of its total operating expenses (OPEX). Of this amount, EUR 0 of Sartorius Stedim Biotech's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Sartorius Stedim Biotech's Taxonomy-Eligible Opex Over Time
Total Taxonomy Eligible Opex
Total Taxonomy Aligned Opex
Have Sartorius Stedim Biotech's increased its spending in sustainable activities over time?
Compared to the previous year (2024), Sartorius Stedim Biotech's taxonomy-aligned OPEX decreased by 100%, suggesting that Sartorius Stedim Biotech may have reduced spending on environmentally sustainable activities, adjusted its operational priorities, or decreased the scope of its taxonomy-related disclosures.a, b
Want Full Access to Sartorius Stedim Biotech's EU Taxonomy Dataset?
b
b
b
b
b